July 12, 2021 – The U.S. FDA has approved a new indication for Janssen’s Darzalex Faspro® (daratumumab/
hyaluronidase-fihj) to be used in combination with pomalidomide
July 2, 2021 – The U.S. FDA has approved an expanded indication for Merck’s Bridion® (sugammadex),
which is used to reverse neuromuscular blockade induced by rocuronium
July 1, 2021 – The U.S. FDA has approved a new indication for Noxafil® (posaconazole – Merck)
intravenous (IV) injection and delayed-release oral tablets